TODD STRATEGY GROUP
TODD STRATEGY GROUP filed a Q3 report for BIOGEN, INC. on October 19, 2026, reporting $50,000 in lobbying income.
Lobbying for BIOGEN, INC. · Biotechnology Company.
-
PAUL EDATTELPreviously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
-
DANIEL M TODDPreviously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
ERIC BERGRENPreviously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
KATHERINE FLEMING COTTONPreviously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
-
NICHOLAS UEHLECKEPreviously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
NICOLAS MAGALLANESPreviously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander
Issues related to Alzheimer's disease and dementia, including screening, diagnosis, and care. Issues related to postpartum depression screening, detection, and education. Issues related to ALS, lupus, and kidney disease policy.
IRA implementation. Issues related to drug pricing. 340B Program. Supply Chain. Issues related to patient affordability and access including copay and coverage reform. Issues related to PBM reform. PDUFA, drug reviews, approval pathways, PPRV Program, clinical trials. Issues related to rare diseases, including the Orphan Drug and ORPHAN CURES Act, rare disease research and screening, and patient access to therapies.